TNSN02003A1 - COMBINATION OF A HISTAMINE H1 RECEPTOR ANTAGONIST AND A SELECTIVE HISTAMINE H4 ANTAGONIST, AND COMPOSITION CONTAINING THE SAME. - Google Patents

COMBINATION OF A HISTAMINE H1 RECEPTOR ANTAGONIST AND A SELECTIVE HISTAMINE H4 ANTAGONIST, AND COMPOSITION CONTAINING THE SAME.

Info

Publication number
TNSN02003A1
TNSN02003A1 TNTNSN02003A TNSN02003A TNSN02003A1 TN SN02003 A1 TNSN02003 A1 TN SN02003A1 TN TNSN02003 A TNTNSN02003 A TN TNSN02003A TN SN02003 A TNSN02003 A TN SN02003A TN SN02003 A1 TNSN02003 A1 TN SN02003A1
Authority
TN
Tunisia
Prior art keywords
histamine
antagonist
combination
composition containing
same
Prior art date
Application number
TNTNSN02003A
Other languages
French (fr)
Inventor
Jenkinson Stephen
Anthony O'reilly Mark
Andrew Trevethick Michael
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN02003A1 publication Critical patent/TNSN02003A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

L'INVENTION PROPOSE UNE ASSOCIATION (a) D'UN ANTAGONISTE DES RECEPTEURS D'HISTAMINE H1 ET (b) D'UN ANTAGONISTE QUI EST AU MOINS 10 FOIS PLUS SELECTIF POUR LE RECEPTEUR D'HISTAMINE H4 QUE POUR LE RECEPTEUR D'HISTAMINE H3. ELLE CONCERNE EGALEMENT UNE COMPOSITION PHARMACEUTIQUE LA CONTENANT. APPLICATION : UTILISATION DE CETTE ASSOCIATION OU COMPOSITION POUR LE TRAITEMENT DE DIVERSES MALADIES, TELLES QUE LA RHINITE ALLERGIQUE OU L'ASTHME.THE INVENTION PROPOSES A COMBINATION (a) OF AN ANTAGONIST OF HISTAMINE H1 RECEPTORS AND (b) OF AN ANTAGONIST THAT IS AT LEAST 10 TIMES MORE SELECTIVE FOR THE HISTAMINE H4 RECEPTOR THAN FOR THE HISTAMINE H3 RECEPTOR . IT ALSO CONCERNS A PHARMACEUTICAL COMPOSITION CONTAINING IT. APPLICATION: USE OF THIS ASSOCIATION OR COMPOSITION FOR THE TREATMENT OF VARIOUS ILLNESSES, SUCH AS ALLERGIC RHINITIS OR ASTHMA.

TNTNSN02003A 2001-01-17 2002-01-16 COMBINATION OF A HISTAMINE H1 RECEPTOR ANTAGONIST AND A SELECTIVE HISTAMINE H4 ANTAGONIST, AND COMPOSITION CONTAINING THE SAME. TNSN02003A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0101223.6A GB0101223D0 (en) 2001-01-17 2001-01-17 Histamine receptor antagonists

Publications (1)

Publication Number Publication Date
TNSN02003A1 true TNSN02003A1 (en) 2005-12-23

Family

ID=9906993

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN02003A TNSN02003A1 (en) 2001-01-17 2002-01-16 COMBINATION OF A HISTAMINE H1 RECEPTOR ANTAGONIST AND A SELECTIVE HISTAMINE H4 ANTAGONIST, AND COMPOSITION CONTAINING THE SAME.

Country Status (31)

Country Link
EP (1) EP1353657A1 (en)
JP (1) JP2004517883A (en)
KR (1) KR20030069216A (en)
CN (1) CN1486178A (en)
AP (1) AP2002002401A0 (en)
AR (1) AR032101A1 (en)
BG (1) BG107834A (en)
BR (1) BR0206502A (en)
CA (1) CA2435121A1 (en)
CR (1) CR6983A (en)
CZ (1) CZ20031853A3 (en)
DO (1) DOP2002000325A (en)
EA (1) EA200300537A1 (en)
EC (1) ECSP034692A (en)
EE (1) EE200300335A (en)
GB (1) GB0101223D0 (en)
GT (1) GT200200003A (en)
HU (1) HUP0302767A2 (en)
IL (1) IL156087A0 (en)
IS (1) IS6818A (en)
MA (1) MA26980A1 (en)
MX (1) MXPA03006408A (en)
NO (1) NO20033223L (en)
OA (1) OA12440A (en)
PA (1) PA8537101A1 (en)
PL (1) PL362793A1 (en)
SK (1) SK8572003A3 (en)
SV (1) SV2003000849A (en)
TN (1) TNSN02003A1 (en)
WO (1) WO2002056871A2 (en)
ZA (1) ZA200304180B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133931A1 (en) * 2001-12-21 2003-07-17 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
CA2497788A1 (en) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. Use of histamine h4 receptor modulators for the treatment of allergy and asthma
WO2004066960A2 (en) * 2003-01-28 2004-08-12 Schering Corporation Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2858647B1 (en) 2012-06-08 2018-05-23 Sensorion H4 receptor inhibitors for treating tinnitus

Also Published As

Publication number Publication date
SK8572003A3 (en) 2004-07-07
EP1353657A1 (en) 2003-10-22
DOP2002000325A (en) 2003-01-31
MXPA03006408A (en) 2003-10-15
KR20030069216A (en) 2003-08-25
MA26980A1 (en) 2004-12-20
CR6983A (en) 2003-11-25
PA8537101A1 (en) 2002-08-29
ZA200304180B (en) 2004-06-15
IL156087A0 (en) 2003-12-23
SV2003000849A (en) 2003-01-13
JP2004517883A (en) 2004-06-17
IS6818A (en) 2003-05-15
GB0101223D0 (en) 2001-02-28
AP2002002401A0 (en) 2002-03-31
AR032101A1 (en) 2003-10-22
GT200200003A (en) 2002-08-19
PL362793A1 (en) 2004-11-02
NO20033223D0 (en) 2003-07-16
NO20033223L (en) 2003-07-16
CN1486178A (en) 2004-03-31
BR0206502A (en) 2003-10-21
CZ20031853A3 (en) 2004-07-14
WO2002056871A2 (en) 2002-07-25
EA200300537A1 (en) 2004-02-26
ECSP034692A (en) 2003-08-29
BG107834A (en) 2004-01-30
EE200300335A (en) 2003-12-15
CA2435121A1 (en) 2002-07-25
HUP0302767A2 (en) 2003-11-28
OA12440A (en) 2006-05-22

Similar Documents

Publication Publication Date Title
TNSN01068A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES COMPRISING COGNITIVE DYSFUNCTION
FR2814678B1 (en) COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY
DE69531998D1 (en) STEROID RECEPTOR MODULATOR CONNECTIONS AND METHODS
NO20034230L (en) 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists
TNSN98017A1 (en) SULFONYLUREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
MA31016B1 (en) DIAZEPAN COMPOUNDS SUBSTITUTED AS ANTAGONISTS OF OREXIN RECEPTORS.
MA31089B1 (en) Antibodies are anti-notch3 antagonists and its occurrence is used in the prevention and treatment of diseases related to notch3.
TNSN98179A1 (en) DRUGS
TNSN01173A1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING AN NMDA RECEPTOR ANTAGONIST.
TNSN00183A1 (en) COMPOSITIONS COMPRISING THE POLYPEPTIDE IL-1ra AND AN IL-1 MATURATION AND RELEASE INHIBITOR AND METHODS OF TREATMENT USING THE SAME
BR9813957A (en) Use of vasopressin antagonists
YU7797A (en) Combination therapy for osteosis
TNSN98227A1 (en) PHARMACEUTICAL ASSOCIATION FOR THE TREATMENT OF SEXUAL DYSFUNCTION AND COMPOSITIONS CONTAINING SAME.
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
MA27101A1 (en) ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF AGOMELATIN
MA29487B1 (en) PREPARATION OF STABLE EMULSION TYPE
TNSN02003A1 (en) COMBINATION OF A HISTAMINE H1 RECEPTOR ANTAGONIST AND A SELECTIVE HISTAMINE H4 ANTAGONIST, AND COMPOSITION CONTAINING THE SAME.
DE69906944D1 (en) 20-HETE ANTAGONISTS AND AGONISTS
MY135916A (en) Use of certain affinity nmda antagonists as antidepressants
ATE348812T1 (en) QUINOLINE AND QUINAZOLINE DERIVATIVES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF)
ATE266420T1 (en) COMBINATION PREPARATION CONTAINING SELECTIVE NMDA NR2B ANTAGONISTS AND COX-2 INHIBITORS
BR0015980A (en) Agent for prophylaxis or treatment of glaucoma, and, use of an angiotensin ii antagonist
YU39201A (en) USE OF 1-arylpyrazole for the preparation of an oral parasite suppressant
BR0212582A (en) Combination
BR0213183A (en) Use of gp130 activators in diabetic neuropathy